Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
2016; Elsevier BV; Volume: 128; Issue: 22 Linguagem: Inglês
10.1182/blood.v128.22.4382.4382
ISSN1528-0020
AutoresBarbara Eichhorst, Jasmin Bahlo, Christian Maurer, Elisabeth Lange, H. Köppler, Michael Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens‐Martin Wendtner, Wolfram Klapper, Karl‐Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek,
Tópico(s)Lymphoma Diagnosis and Treatment
Referência(s)